> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Verrica Positive Data from Skin Cancer Trial
- URL: https://www.fdaweb.com/verrica-positive-data-from-skin-cancer-trial/
- Published: 2024-08-14T12:00:00.000Z
- Updated: 2026-09-14T14:38:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157573

Verrica Pharmaceuticals says it will request an end-of-Phase 2 meeting with FDA after reporting “preliminary positive results” from Part 2 of its Phase 2 clinical trial studying VP-315, a potential first-in-class oncolytic peptide for treating basal cell carcinoma. The company says it expects genomic and T-cell (immune response) data in the first quarter of 2025 and plans to request the FDA meeting at that time to determine next steps for developing the therapy.

“We are encouraged by our preliminary results, which we believe support the use of VP-315 as a first-line therapy for use in both a primary and neoadjuvant setting,” the company says. “The preliminary results from Part 2 of the trial show greater than 50% complete histological clearance and a significant reduction in tumor size for tumors treated in the study, which we believe has the potential to vastly improve patient outcomes versus current therapies and surgical procedures.”

VP-315 is designed to be administered directly into a tumor to induce immunogenic cell death, the company says, adding that it could offer a non-surgical option for patients suffering from the skin cancer.